Trial reportAddiction (Abingdon, England)2022
Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial.
Trial report in Addiction (Abingdon, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Combatting opioid misuse, overuse and abuse: a systematic review of pharmacists' services and outcomes.Pain management · 2024Pooled it
- A Novel Role of Dexmedetomidine in the Modulation of Morphine Reward Memory via γ-Aminobutyric Acid Transporter-1.Anesthesiology · 2026Article
- Envisioning a Humane and Accessible US Methadone Treatment System: Generating Policy and Practice Recommendations From the Liberate Methadone Movement.Substance use & addiction journal · 2026Article
- Treating Opioid Use Disorder With Methadone in Pharmacies.JAMA network open · 2026Article
- Barriers and facilitators to methadone dispensing for opioid use disorder in community pharmacies: A scoping review.Drug and alcohol dependence reports · 2026Review
- Key-Informant Perspectives On Pharmacy-Based Methadone Treatment For Opioid Use Disorder In The US.Health affairs (Project Hope) · 2025Article
- Community pharmacist-administered injectable naltrexone for individuals who were formerly incarcerated: a review of Wisconsin legislation and regulations.Substance abuse treatment, prevention, and policy · 2025Review
- Physical and Mental Health Services in Opioid Treatment Programs.Journal of general internal medicine · 2025Article
- Correction: Rapid Assessment Amid an Injection Drug Use-Driven HIV Outbreak in Massachusetts' Merrimack Valley: Highlights from a Case Study.AIDS and behavior · 2025Article
- Rapid Assessment Amid an Injection Drug Use-Driven HIV Outbreak in Massachusetts' Merrimack Valley: Highlights from a Case Study.AIDS and behavior · 2025Article
- Community pharmacy's role in dispensing androgens and supporting harm reduction amid current policy dilemmas.Substance abuse treatment, prevention, and policy · 2025Article
- "Yeah, this is not going to work for me"-The impact of federal policy restrictions on methadone continuation upon release from jail or prison.Journal of substance use and addiction treatment · 2025Article
- Article
- Single-Cell RNA Transcriptomics and Multi-omics Analyses Reveal the Clinical Effects of Acupuncture on Methadone Reduction.Research (Washington, D.C.) · 2025Article
- Pharmacy-based preventive services for opioid use disorder: a survey of U.S. pharmacists.Addiction science & clinical practice · 2024Article
- U.S. Healthcare Workers' Perspective of Outpatient Provision of Methadone: A Scoping Review.Substance use & addiction journal · 2024Article
- Delivering MOUD to the Underserved: How Can Pharmacies Really Help?Journal of studies on alcohol and drugs · 2024Article
- Persistence in the Methadone Maintenance Program and Its Relationship with the Medication Regimen Complexity Index in Opioid-Dependent Patients.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Mobile treatment for opioid use disorder: Implementation of community-based, same-day medication access interventions.Journal of substance use and addiction treatment · 2024Article
- Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs.Drug and alcohol dependence reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsPharmacy administration and dispensing of methadone for methadone maintenance treatment (MMT) can expand treatment access for opioid use disorder (OUD). This study investigated the feasibility and acceptability of a novel model permitting an opioid treatment program (OTP) physician to prescribe methadone for OUD treatment through collaboration with a partnered pharmacy.
designNon-randomized, single-arm, open-label feasibility trial.
settingOne OTP and one community pharmacy in the United States.
participantsOne OTP physician, two pharmacists and 20 MMT patients receiving between six and 13 take-home methadone doses at 5-160 mg/day.
interventionPatients' methadone administration and dispensing of take-home doses was transferred from the OTP to the pharmacy for 3 months. MEASUREMENTS: Primary outcome was medication adherence. Secondary outcomes were recruitment, treatment retention, substance use, counseling attendance at the OTP, pharmacist prescription drug monitoring program (PDMP) use, safety and satisfaction.
findingsOf 29 patients eligible at pre-screen, 20 patients (69%) enrolled into the study. Recruitment occurred from 6 August 2020 to 10 October 2020. Treatment retention rate at month 3 was 80% (16 of 20). Two participants returned early to the OTP because of a work/schedule change, one due to pregnancy and one following a non-study-related hospitalization. Medication adherence among 16 patients who were retained was 100%. Intervention fidelity was 100%. All participants attended random call-back visits. None showed evidence of tampering/diversion of methadone. Pharmacists checked the PDMP at all visits. All participants attended psychosocial counseling as planned. There were no positive urine screens for illicit opioid use and no study-related adverse events. All participants endorsed 'pharmacy is the right location for receiving methadone for MMT', 88% endorsed 'convenient or very convenient to receive methadone at the pharmacy' and 88% were satisfied or very satisfied with the quality of treatment offered.
conclusionsThis feasibility trial has found pharmacy administration and dispensing of physician-prescribed methadone for methadone maintenance treatment to be feasible and acceptable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.